Edition:
United States

Keryx Biopharmaceuticals Inc (KERX.PH)

KERX.PH on Philadelphia Stock Exchange

6.26USD
13 Jan 2017
Change (% chg)

$0.05 (+0.81%)
Prev Close
$6.21
Open
$6.37
Day's High
$6.37
Day's Low
$6.23
Volume
14,078
Avg. Vol
12,543
52-wk High
$7.79
52-wk Low
$2.82

Select another date:

Wed, Nov 9 2016

BRIEF-Keryx Biopharmaceuticals says U.S. FDA approves second contract manufacturer for Auryxia

* Keryx biopharmaceuticals -patheon manufacturing services llc is now an fda approved drug product manufacturer of auryxia

BRIEF-Keryx Biopharmaceuticals announces third quarter 2016 financial results

* Keryx Biopharmaceuticals announces third quarter 2016 financial results and provides corporate update

BRIEF-Keryx Biopharmaceuticals files for mixed shelf of up to $250 million

* Keryx Biopharmaceuticals Inc - Files for mixed shelf of up to $250 million - SEC filing Source text: [http://bit.ly/2ff1wha] Further company coverage:

BRIEF-Keryx Biopharmaceuticals and Patheon Manufacturing Services, it affiliates entered into a Master Manufacturing Services

* Keryx Biopharmaceuticals - Co, Patheon Manufacturing Services, it affiliates of entered into a Master Manufacturing Services, 2 product agreements

Keryx withdraws 2016 forecast on renal drug supply disruption

Keryx Biopharmaceuticals Inc withdrew its full-year forecast due to a disruption in production of its only approved drug, Auryxia, sending its shares down by more than a third in morning trading on Monday.

UPDATE 2-Keryx withdraws 2016 forecast on renal drug supply disruption

* Shares fall by a third (Adds analyst comment; updates shares)

BRIEF-Keryx Biopharmaceuticals withdraws 2016 financial guidance

* Company announces interruption in supply of Auryxia(ferric citrate)

Keryx withdraws 2016 forecast on renal drug supply interruption

Aug 1 Keryx Biopharmaceuticals Inc said it was withdrawing its full-year forecast due to issues related to the production of its only approved drug, Auryxia.

Select another date: